Janssen Cilag International

Haematologic Malignancies and Blood Disorders

Multiple myeloma, relapsed or refractory myeloma, chronic lymphocytic leukemia, small lymphocytic lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic neoplasms, and AL amyloidosis are prominent areas of interest, alongside studies in mantle cell lymphoma and other B-cell malignancies.

  • Multiple myeloma and plasma cell disorders
  • B-cell non-Hodgkin lymphoma and CLL/SLL
  • Acute leukemia and myelodysplastic neoplasms

Research also extends to warm autoimmune hemolytic anemia and other haematology-focused conditions.

Oncology in Solid Tumours

The sponsor funds research in non-small cell lung cancer, prostate cancer, urothelial cancer, bladder cancer, colorectal cancer, head and neck squamous cell carcinoma, and other advanced solid tumors, including metastatic and recurrent disease settings.

  • Non-small cell lung cancer
  • Prostate cancer
  • Urothelial and bladder cancers

Additional activity includes studies in gastric cancer, advanced solid tumors, and biomarker-defined tumour populations.

Immune-Mediated and Inflammatory Diseases

Clinical research includes psoriasis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s disease, and idiopathic inflammatory myopathies, with both adult and paediatric populations represented.

  • Psoriasis and psoriatic arthritis
  • Inflammatory bowel disease
  • Systemic autoimmune and rheumatologic disease

Work also covers atopic dermatitis, asthma, and chronic inflammatory demyelinating polyneuropathy.

Neurology, Psychiatry, and Ophthalmology

Janssen Cilag International supports studies in Alzheimer’s disease, major depressive disorder, bipolar depression, myasthenia gravis, chronic inflammatory neuropathies, and stroke prevention, together with ophthalmic research in geographic atrophy and X-linked retinitis pigmentosa.

  • Alzheimer’s disease and cognitive decline
  • Depression and related mood disorders
  • Neuromuscular and retinal disorders

Further interest includes acute suicidal ideation and healthy volunteer studies supporting neurological and psychiatric development.

Cardiovascular, Maternal, Infectious, and Metabolic Conditions

The portfolio also includes atrial fibrillation, acute coronary syndrome, atherothrombotic and thromboembolic disorders, acute ischemic stroke, and metastatic castration-sensitive prostate cancer with cardiovascular-relevant treatment questions, as well as maternal-fetal conditions such as hemolytic disease of the fetus and newborn and fetal and neonatal alloimmune thrombocytopenia.

  • Atrial fibrillation and ischemic stroke
  • Maternal-fetal haematology
  • Hepatitis B and hepatitis D co-infection

Research activity also includes tuberculosis, renal impairment, and healthy adult participant studies relevant to drug disposition and clinical use.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease

    Not recruiting

    3 1
    Investigated drugs:
    Austria Bulgaria Czechia Denmark France Germany +9
  • Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Denmark Germany Hungary Poland +2
  • Study of Bleximenib with Drug Combination for Patients with Acute Myeloid Leukemia with KMT2A or NPM1 Alterations

    Not recruiting

    1 1 1 1
    France Germany Italy Spain
  • Study on the Effectiveness and Safety of JNJ-95475939 and Dupilumab for Treating Moderate to Severe Atopic Dermatitis in Adults

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Poland Spain
  • Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

    Not recruiting

    3 1 1
    Investigated drugs:
    Bulgaria Czechia Denmark Germany Hungary Poland +1
  • Study on Ustekinumab and Guselkumab for Children with Active Juvenile Psoriatic Arthritis

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Denmark France Germany Italy The Netherlands Poland +1